SecBot SecBot
PRESS-RELEASE ·Filed Apr 1, 2026

OCUL

Ocular Therapeutix, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor the April 11 and April 15 presentations for any new efficacy or safety data from the SOL-1 trial, which could influence sentiment around AXPAXLI™'s regulatory and commercial potential. Absent data or approval, this filing is routine scientific communication.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.33
T+0 close · Apr 1, 2026 · via day close
Latest settled
+18.85%
T+60 · $9.90
Vs SPY
+5.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $8.33entry
  2. T+1 · 8mo ago +1.92%α +1.84% · $8.49
  3. T+5 · 7mo ago +11.64%α +7.88% · $9.30
  4. T+20 · 7mo ago +10.56%α +0.84% · $9.21
  5. T+60 · 5mo ago +18.85%α +5.47% · $9.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) in wet AMD at major ophthalmology conferences in April 2026. The data disclosures are part of ongoing scientific dissemination, not a regulatory approval or clinical trial result announcement.

Key Facts

  • Ocular Therapeutix will present SOL-1 Phase 3 data for AXPAXLI™ (OTX-TKI) in wet AMD at the Vit-Buckle Society meeting on April 11, 2026.
  • Additional presentations on diabetic retinal disease and wet AMD will occur at CNO 2026 in Buenos Aires from April 15–17, 2026.
  • AXPAXLI™ is an axitinib intravitreal hydrogel in Phase 3 trials for wet AMD and diabetic retinal disease, including NPDR.
  • No new clinical data, FDA decision, or commercial update was released, this is a schedule of upcoming scientific presentations.

Financial Impact

Minimal near-term financial impact; no revenue or cost implications disclosed

Risk Factors

  • Data presented at the conferences could reveal safety concerns or lower-than-expected efficacy for AXPAXLI™
  • Failure to show superiority over existing anti-VEGF therapies could limit commercial adoption

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3266467

Track record

20 reports on OCUL

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
  3. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
  6. Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
  7. Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
  8. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
  9. Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
  10. Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026